Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 14/20 | 0.78 |
| ▸ | ITGB1 | P05556 | 10/20 | 0.78 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.49 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.49 |
| ▸ | ITGAL | P20701 | 1/20 | 0.49 |
| ▸ | ITGB7 | P26010 | 9/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6239694 | 0.93 | ITGB1 (0.68) | ITGA4ITGB1ITGB2ICAM1ITGAL | |
| SCHEMBL5162599 | 0.89 | ITGA4 (0.74) | ITGA4ITGB1ITGB2ICAM1ITGAL | |
| SCHEMBL4892883 | 0.88 | ITGA4 (1.00) | ITGA4ITGB1ITGB2ICAM1ITGAL | |
| SCHEMBL27487814 | 0.85 | ITGA4 (0.57) | ITGA4ITGB1ITGB7 | |
| SCHEMBL6240483 | 0.81 | ITGA4 (0.87) | ITGA4ITGB1ITGB2ICAM1ITGAL | |
| SCHEMBL5133478 | 0.80 | ITGA4 (0.79) | ITGA4ITGB1ITGB2ICAM1ITGAL | |
| SCHEMBL27567849 | 0.78 | ITGA4 (0.49) | ITGA4ITGB1ITGB7 | |
| SCHEMBL7418261 | 0.75 | ITGA4 (0.61) | ITGA4ITGB1ITGB2ICAM1ITGAL | |
| SCHEMBL7415187 | 0.75 | ITGB1 (0.61) | ITGA4ITGB1ITGB2ICAM1ITGAL | |
| SCHEMBL4649064 | 0.74 | ITGA4 (0.59) | ITGA4ITGB1ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6916933-B2 | 4-pyridinyl-n-acyl-l-phenylalanines | HOFFMAN-LA ROCHE INC. (US) | 2005-07-12 | — | — | US | claimed |
| EP-1244625-B1 | 4-PYRIDINYL-N-ACYL-L-PHENYLALANINES | HOFFMANN LA ROCHE (CH) | 2005-06-15 | — | — | EP | claimed |
| US-20040127706-A1 | 4-Pyridinyl-n-acyl-l-phenylalanines | KAPLAN GERALD LEWIS (US) | 2004-07-01 | — | — | US | claimed |
| US-20020133015-A1 | 4-pyridinyl-N-acyl-L-phenylalanines | KAPLAN GERALD LEWIS (US) | 2002-09-19 | — | — | US | claimed |
| US-20140051655-A1 | METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH ALPHA-4 INHIBITORY COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8410115-B2 | Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds | ELAN PHARMACEUTICALS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20080044382-A1 | Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2008-02-21 | — | — | US | disclosed |
| US-6916933-B2 | 4-pyridinyl-n-acyl-l-phenylalanines | HOFFMAN-LA ROCHE INC. (US) | 2005-07-12 | — | — | US | disclosed |
| EP-1244625-B1 | 4-PYRIDINYL-N-ACYL-L-PHENYLALANINES | HOFFMANN LA ROCHE (CH) | 2005-06-15 | — | — | EP | disclosed |
| US-20040127706-A1 | 4-Pyridinyl-n-acyl-l-phenylalanines | KAPLAN GERALD LEWIS (US) | 2004-07-01 | — | — | US | disclosed |
| US-20020133015-A1 | 4-pyridinyl-N-acyl-L-phenylalanines | KAPLAN GERALD LEWIS (US) | 2002-09-19 | — | — | US | disclosed |
| US-6388084-B1 | 4-pyridinyl-n-acyl-l-phenylalanines | HOFFMANN-LA ROCHE INC. | 2002-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051655-A1 | METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH ALPHA-4 INHIBITORY COMPOUNDS | IL4, PSMA4, SCN4A | ITGA4 27/4885ITGB1 277/4885ITGB2 718/4885 |
| US-20040127706-A1 | 4-Pyridinyl-n-acyl-l-phenylalanines | VCAM1, ICAM1, SELPLG | ITGA4 8/4885ITGB1 13/4885ITGB2 42/4885 |
| US-20080044382-A1 | Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds | IL4, PSMA4, SCN4A | ITGA4 27/4885ITGB1 277/4885ITGB2 718/4885 |
| US-20020133015-A1 | 4-pyridinyl-N-acyl-L-phenylalanines | VCAM1, ICAM1, SELPLG | ITGA4 8/4885ITGB1 13/4885ITGB2 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.